Table 5 Validation of SAPS II for 28-day and 60-month mortality according to the indication
|  | Overall (N = 65) | E-CPR (N = 35) | VA and V-AV (N = 20) | VV (N = 10) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Survivor (N = 31) | Death (N = 34) | p-value <0.001 | Survivor (N = 10) | Death (N = 25) | p-value 0.004 | Survivor (N = 11) | Death (N = 8) | p-value 0.005 | Survivor (N = 9) | Death (N = 1) | p-value 0.100 | |
28-day mortality | Â | Â | Â | Â | ||||||||
 SAPS II ≤80 | 22 (71.0) | 1 (2.9) |  | 5 (50.0) | 1 (4.0) |  | 8 (66.7) | 0 (0.0) |  | 9 (100.0) | 0 (0.0) |  |
 SAPS II >80 | 9 (29.0) | 33 (97.1) |  | 5 (50.0) | 24 (96.0) |  | 4 (33.3) | 8 (100.0) |  | 0 (0.0) | 1 (100.0) |  |
60-month mortality | Â | Â | Â | Â | ||||||||
 SAPS II ≤80 | 19 (79.2) | 4 (9.8) |  | 4 (66.7) | 2 (6.9) |  | 7 (70.0) | 1 (10.0) |  | 8 (100.0) | 1 (50.0) |  |
 SAPS II >80 | 5 (20.8) | 37 (90.2) |  | 2 (33.3) | 27 (93.1) |  | 3 (30.0) | 9 (90.0) |  | 0 (0.0) | 1 (50.0) |  |